Bioasis Technologies Inc. V.BTI

RE:RE:RE:RE:RE:Accountability for Low-value Deals

[chrispi]

prophetoffact wrote: So, total it all up and it could be a well over $600 million deal and BTI doesn't have to invest in it anymore and can license other companies and pursue its own Parkinson's drug.

prophetoffact wrote: Assuming the Levodopa revenue is right and BTI was entitled to a 5% royalty BTI could receive C$91 million in milestone payments and up to or more than C$170 million in annual royalty payments if the drug reached similar revenue levels to Levodopa.  


"Levodopa/Carbidopa segment revenue was around USD 2.64 billion in 2020."

"Parkinson’s Disease Therapeutic Market size is set to surpass USD 8 billion by 2027, according to a new research report by Global Market Insights Inc."

Parkinson’s Disease Therapeutic Market worth over $8bn by 2027 (gminsights.com)
 

Well I have to side with prophetoffact on this one. LIke he says, total it all up and it could be a well over $600 million deal and BTI doesn't have to invest in it anymore and can license other companies and pursue its own Parkinson's drug.
That's the key, this is a non-exclusive deal in the Parkinson's space. Who cares if it isn't the best deal that Bioasis has every publicly announced, we don't even know that b/c all the details like upfront $ weren't stated. It doesn't matter as it is a one off with non-exclusivity so it doesn't imply that every PD drug maker is going to get the same terms or anything close.

And about that "not including the upfront $" in the PR, given that the market anticipates other deals coming, why release specific terms for this deal that could influence other active deals. What terms Neuramedy got are not available for others - one off, special situation, and not a bad deal as prophetoffacts stated with $600+ possible and not a penny spent by Bioasis or exclusion from us or others entering the Parkinson's space.